Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,044.54 +26.15 (+0.52%) Dow
38,122.82 +219.53 (+0.58%) Nasdaq
15,745.29 +139.81 (+0.90%) Bitcoin USD
59,206.38 +2,121.00 (+3.72%) CMC Crypto 200
1,272.90 +2.16 (+0.17%)
Bio-Rad Laboratories, Inc. (BIO-B)
| Previous close | 279.91 |
| Open | 281.55 |
| Bid | 274.20 x 1400 |
| Ask | 284.90 x 800 |
| Day's range | 279.91 - 281.55 |
| 52-week range | 271.00 - 467.95 |
| Volume | |
| Avg. volume | 280 |
| Market cap | 7.846B |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -21.83 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksEarnings Preview: National Vision (EYE) Q1 Earnings Expected to Decline
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireBio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
HERCULES, Calif., May 01, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 2:05 PM Eastern Time (11:05 AM Pacific Time).
ZacksAnalysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
